腺病毒载体新冠疫苗（康希诺生物）接种后异源加强免疫接种的有效性和安全性：一项初步描述性研究
Efficacy and Safety of Heterologous Booster Vaccination after Ad5-nCoV (CanSino Biologics) Vaccine: A Preliminary Descriptive Study.
作者信息
Muñoz-Valle José Francisco, Sánchez-Zuno Gabriela Athziri, Matuz-Flores Mónica Guadalupe, Hernández-Ramírez Cristian Oswaldo, Díaz-Pérez Saúl Alberto, Baños-Hernández Christian Johana, Turrubiates-Hernández Francisco Javier, Vega-Magaña Alejandra Natali, Hernández-Bello Jorge
机构信息
Institute of Research in Biomedical Sciences, University Center of Health Sciences (CUCS), University of Guadalajara, Guadalajara 44340, Mexico.
出版信息
Vaccines (Basel). 2022 Mar 5;10(3):400. doi: 10.3390/vaccines10030400.
Several studies have reported the benefits and safety of heterologous vaccination among different approved vaccines; however, there are no specific reports on the effects of vaccination with the Ad5-nCoV and other vaccines of the same or different technologies. In the present study, we evaluated the neutralizing antibodies percentage against SARS-CoV-2 in Mexican patients immunized with the Ad5-nCoV vaccine six months after its application. Moreover, the effect of the heterologous vaccination with the Ad5-nCoV vaccine and a booster dose of ChAdOx1-S-Nov-19, Ad26.COV2.S, BNT162b2, or mRNA-127 were determined. Our results suggest that a heterologous regimen of one dose with Ad5-nCoV vaccine followed by a booster dose of a different vaccine is safe and induces a stronger humoral immune response.
多项研究报告了不同获批疫苗进行异源接种的益处和安全性；然而，关于接种Ad5-nCoV疫苗以及其他相同或不同技术的疫苗的效果，尚无具体报告。在本研究中，我们评估了墨西哥患者在接种Ad5-nCoV疫苗六个月后针对SARS-CoV-2的中和抗体百分比。此外，还确定了用Ad5-nCoV疫苗进行异源接种以及ChAdOx1-S-Nov-19、Ad26.COV2.S、BNT162b2或mRNA-127加强剂量的效果。我们的结果表明，一剂Ad5-nCoV疫苗随后接种一剂不同疫苗的异源接种方案是安全的，并能诱导更强的体液免疫反应。
Zotero 插件